The cellular and molecular mechanisms underlying the telomerase-independent Alternative Lengthening of Telomeres (ALT) telomere maintenance mechanism is an area of active research, particularly in non-epithelial cancers where ALT is commonly found (e.g. gliomas, sarcomas, pancreatic neuroendocrine tumors). For many of these cancers the prognosis is poor and therapeutic options are limited. Encouraging results from a recent pre-clinical study show a pharmacological inhibitor of the DNA Damage Response (DDR) protein, ATR, exhibits selective toxicity against osteosarcoma and glioblastoma cancer cells that utilize the ALT pathway for telomere maintenance, instead of up-regulating the enzyme, telomerase. Less appreciated and under- investigated are adenocarcinomas that employ the ALT pathway. We hypothesize that ALT-positive adenocarcinomas share molecular features with ALT-positive cancers of non-epithelial origin, and that these similarities will result in a comparable sensitivity to ATR inhibition. The overarching goal of this proposal is to study ALT in adenocarcinomas, using prostate cancer cell lines as an initial in vitro model system, to investigate whether similar strategies of pharmacologically inhibiting DDR proteins, such as ATR, in ALT-positive adenocarcinomas will also show efficacy.
In Aim 1, we will generate and validate the first adenocarcinoma cell lines that employ ALT. Our laboratory previously discovered a strong correlation between ALT-positive tumors and somatic inactivating mutations in either the ATRX and DAXX genes. To date, no prostate cancer cell line has been identified that displays the ALT phenotype. Using the CRISPR cas9 genome editing technique, we will create isogenic prostate cancer cell lines with inactivating mutations in ATRX or DAXX genes.
In Aim 2, we will characterize the molecular features underlying the ALT process in prostate cancer cells by comparing the telomerase-positive/ALT-negative parental lines for differences in the relative expression of telomerase components, telomerase activity, nuclear architecture, and activity levels of homology-directed recombination, which is thought to be crucial to the ALT pathway. Finally, in Aim 3, we will evaluate the response of ALT-positive prostate cancer cells to DDR inhibition. Preliminary evidence shows a dramatically activated DDR in ALT-positive cells, suggesting that an increase in the level of DNA damage or a reduction in repair capacity in these already stressed cells may be sufficient to induce apoptosis. DDR proteins will be inhibited using RNA interference strategies, as well as existing pharmacological inhibitors in ALT-positive prostate cancer cell lines. The research findings of the proposed study will have real biological and therapeutic value by increasing our understanding of the molecular mechanisms underlying ALT in adenocarcinomas, and by determining if this unique molecular subset of carcinomas is susceptible to enhanced killing by inhibiting DDR proteins.

Public Health Relevance

Encouraging results from a recent pre-clinical study show that a pharmacological inhibitor of the DNA Damage Response protein, ATR, exhibits selective toxicity against non-epithelial cancers, osteosarcoma and glioblastoma cancer cells, that utilize the Alternative Lengthening of Telomeres (ALT) pathway for telomere maintenance, instead of up-regulating the enzyme, telomerase. We hypothesize that ALT-positive adenocarcinomas share molecular features with ALT-positive cancers of non-epithelial origin, and that these similarities will result in a comparable sensitivity to inhibition of DNA Damage Response proteins. Using CRISPR cas9 genome editing techniques, we will generate the first ALT-positive adenocarcinoma cell line from a panel of well-characterized prostate cancer cell lines, validate and molecularly characterize these ALT- positive prostate cancer cells, and investigate the potential therapeutic value of inhibiting DNA Damage Response proteins in these novel ALT-positive prostate cancer sublines.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Postdoctoral Individual National Research Service Award (F32)
Project #
1F32CA213742-01
Application #
9256818
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Mcguirl, Michele
Project Start
2017-01-15
Project End
2019-01-14
Budget Start
2017-01-15
Budget End
2018-01-14
Support Year
1
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Pathology
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21205
Graham, Mindy Kim; Meeker, Alan (2017) Telomeres and telomerase in prostate cancer development and therapy. Nat Rev Urol 14:607-619